Replimune Group (NASDAQ:REPL) Hits New 52-Week High – What’s Next?

Posted by Francis Steltz on Aug 25th, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $15.83 and last traded at $15.8380, with a volume of 2126037 shares changing hands. The stock had previously closed at $14.71.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research note on Friday, August 7th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Tuesday, June 30th. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Replimune Group presently has an average rating of “Moderate Buy” and an average price target of $11.86.

Read Our Latest Analysis on Replimune Group

Replimune Group Trading Up 7.8%

The company has a 50 day simple moving average of $11.36 and a two-hundred day simple moving average of $8.11. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The firm has a market cap of $1.49 billion, a PE ratio of -5.03 and a beta of 0.88.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Analysts expect that Replimune Group, Inc. will post -2.78 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,256 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the transaction, the chief financial officer owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 91,124 shares of company stock valued at $1,149,244. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System grew its stake in shares of Replimune Group by 185.3% during the 2nd quarter. California State Teachers Retirement System now owns 11,114 shares of the company’s stock worth $123,000 after purchasing an additional 7,218 shares during the period. Readystate Asset Management LP lifted its stake in shares of Replimune Group by 116.6% in the 2nd quarter. Readystate Asset Management LP now owns 299,958 shares of the company’s stock valued at $3,321,000 after purchasing an additional 161,470 shares during the period. Syon Capital LLC purchased a new stake in Replimune Group during the second quarter worth $247,000. AXQ Capital LP grew its position in Replimune Group by 4.1% during the second quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after buying an additional 1,056 shares during the period. Finally, Montanova Capital LLC increased its holdings in Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after buying an additional 168,000 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.